Das Sjögren-Syndrom im Fokus

Was ist neu?

Diagnostik – Der Teufel steckt im Detail! Die Speicheldrüsensonografie (SGUS) hat sich in der Diagnostik des Sjögren-Syndroms (SjS) etabliert und kann zu einer höheren Sensitivität der geltenden Klassifikationskriterien führen, gleichwohl sie bislang nicht in die Kriterien aufgenommen wurde. In der Labordiagnostik erhalten die Subspezifizierung von anti-SSA/Ro-Antikörpern – ggf. auch neue Biomarker – eine zunehmende Bedeutung. Präventiv müssen psychische Belastungen im Auge behalten werden, und das kardiovaskuläre Risiko und das Lymphomrisiko spielen eine große Rolle. Mittels Cluster-Analysen konnten verschiedene Phänotyp-Gruppen erschlossen werden, denen sich klinische Parameter zuordnen lassen.

Therapie 2020 wurden Therapieempfehlungen publiziert, die sich an den klinischen Manifestationen des SjS orientieren und Medikamente empfehlen, die auch in der Therapie des systemischen Lupus erythematodes (SLE) oder bei der rheumatoiden Arthritis eingesetzt werden. In den EULAR-Empfehlungen hat die Anti-B-Zell-Therapie mit Rituximab und Belimumab für schwerwiegende Manifestationen Einzug gefunden, und Ianalumab ist ein weiterer aussichtsreicher Wirkstoff. Ein weiterer Schwerpunkt der aktuellen Forschung liegt in der Inhibition der Costimulation zwischen Immunzellen. Nach zuletzt enttäuschenden Ergebnissen von Abatacept sind mit Iscalimab und Dazodalibep aber auch auf dieser Therapieachse aussichtsreiche Wirkstoffe in der Pipeline.

Abstract

In the diagnosis of Sjögren’s syndrome the Salivary gland sonography (SGUS) has become established and can lead to a higher specificity of the applicable classification criteria. The OMERACT score is used to objectify the SGUS findings. In laboratory diagnostics, the subspecification of anti-SSA/Ro antibodies, but possibly also new biomarkers, are becoming increasingly important regarding diagnostic safety and the expected manifestations. When it comes to prevention, it has been shown that not only psychological stress, but also cardiovascular risk and the risk of lymphoma allow high-risk patients to be identified more precisely in the future. Using cluster analyses, various phenotype groups could be identified to which clinical parameters could be assigned. In 2020, therapy recommendations were published that are based on the clinical manifestations of SjS and recommend medications that are also used in the treatment of systemic lupus erythematosus (SLE) or rheumatoid arthritis. A particularly large number of therapeutic approaches are dedicated to the B cell: Rituximab and Belimumab have been included in the EULAR recommendations for serious manifestations and Ianalumab has a promising effect. Another focus of current research is the inhibition of co-stimulation between immune cells. After recent disappointing results for Abatacept, clinical trials show promising effects on Iscalimab and Dazodalibep.

Schlüsselwörter

Sjögren-Syndrom - Diagnostik - SGUS - anti-SSA/Ro-Antikörper - Lymphomrisiko - B-Zell-Therapie - Costimulation

Keywords

sjogren's syndrome - diagnosis - SGUS - anti-SSA/Ro antibodies - lymphoma risk - B cell therapy - co-stimulation

Publication History

Article published online:
23 May 2024

• Literatur

• 1 Shiboski CH, Shiboski SC, Seror R. et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis and Rheumatology 2017; 69: 35-45 DOI: 10.1002/art.39859. (PMID: 27785888)
• 2 Seror R, Theander E, Brun JG. et al. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the Rheumatic Diseases 2015; 74: 859-866 DOI: 10.1136/annrheumdis-2013-204615. (PMID: 24442883)
• 3 Ramos-Casals M, Brito-Zerón P, Bombardieri S. et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79: 3-18 DOI: 10.1136/annrheumdis-2019-216114.
• 4 Izzetti R, Fulvio G, Nisi M. et al. Reliability of OMERACT Scoring System in Ultra-High Frequency Ultrasonography of Minor Salivary Glands: Inter-Rater Agreement Study. J Imaging 2022; 8: 111 DOI: 10.3390/jimaging8040111.
• 5 Fana V, Dohn UM, Krabbe S. et al. Application of the OMERACT Grey-scale Ultrasound Scoring System for salivary glands in a single-centre cohort of patients with suspected Sjögren’s syndrome. RMD Open 2021; 7: e001516 DOI: 10.1136/rmdopen-2020-001516.
• 6 Jousse-Joulin S, Gatineau F, Baldini C. et al. Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren’s syndrome. Journal of internal medicine 2020; 287: 180-188 DOI: 10.1111/joim.12992. (PMID: 31618794)
• 7 Baldini C, Pepe P, Quartuccio L. et al. Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2014; 53: 839-844 DOI: 10.1093/rheumatology/ket427. (PMID: 24369420)
• 8 Zampeli E, Mavrommati M, Moutsopoulos HM. et al. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations. Clin Exp Rheumatol 2020; 38: 134-141 (PMID: 32083547)
• 9 Robbins A, Hentzien M, Toquet S. et al. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases. Front. Immunol 2019; 10: 444 DOI: 10.3389/fimmu.2019.00444.
• 10 Mihai A, Caruntu C, Jurcut C. et al. The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome. Journal of Personalized Medicine 2023; 13: 961 DOI: 10.3390/jpm13060961.
• 11 Seeliger T, Jacobsen L, Hendel M. et al. Cognitive impairment in patients with Neuro-Sjögren. Ann Clin Transl Neurol 2020; 7: 1352-1359 DOI: 10.1002/acn3.51123.
• 12 Novella-Navarro M, Cabrera-Alarcón JL, Rosales-Alexander JL. et al. Primary Sjögren’s syndrome as independent risk factor for subclinical atherosclerosis. Eur J Rheumatol 2022; 9: 20-25 DOI: 10.5152/eurjrheum.2021.20093. (PMID: 35110133)
• 13 Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore) 2016; 95: e3766 DOI: 10.1097/MD.0000000000003766. (PMID: 27336863)
• 14 McCoy SS, Woodham M, Bartels CM. et al. Symptom-Based Cluster Analysis Categorizes Sjögren’s Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance. Arthritis and Rheumatology 2022; 74: 1569-1579 DOI: 10.1002/art.42238. (PMID: 35594474)
• 15 Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A. et al. Primary Sjogren syndrome. BMJ 2012; 344: e3821 DOI: 10.1136/bmj.e3821. (PMID: 22700787)
• 16 Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 2013; 9: 544-556 DOI: 10.1038/nrrheum.2013.110. (PMID: 23857130)
• 17 Bowman SJ, Everett CC, O’Dwyer JL. et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol 2017; 69: 1440-1450 DOI: 10.1002/art.40093. (PMID: 28296257)
• 18 De Vita S, Quartuccio L, Seror R. et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford) 2015; 54: 2249-2256 DOI: 10.1093/rheumatology/kev257. (PMID: 26242856)
• 19 Bowman SJ, Fox R, Dörner T. et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. The Lancet 2022; 399: 161-171 DOI: 10.1016/S0140-6736(21)02251-0.
• 20 van Nimwegen JF, Mossel E, van Zuiden GS. et al. Abatacept treatment for patients with early active primary Sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). The Lancet Rheumatology 2020; 2: e153-e163 DOI: 10.1016/S2665-9913(19)30160-2.
• 21 Fisher BA, Mariette X, Papas AS. et al. Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study. 2023 https://acrabstracts.org/abstract/iscalimab-cfz533-in-patients-with-sjogrens-disease-week-24-efficacy-and-safety-results-of-a-randomized-placebo-controlled-phase-2b-dose-ranging-study
• 22 St Clair E, Wang L, Alevios I. et al. Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement.